SAB Biotherapeutics is trading 9.4% up in pre-market at $3.26 on October 5, 2026, versus its October 2 close of $2.98; no fresh catalyst has been confirmed.
- The latest company release, dated October 1, announced planned SAB-142 presentations featuring encore Phase 1 data at an October 9–11 diabetes research congress; it does not establish a link to the gain.
- Broader US index futures were slightly lower, offering no clear explanation for the move.